Anna Karmann outlines AdvanCell’s Lead-212 alpha-emitting radioligand therapy program, covering the phase one experience and an emerging phase two design. Lead-212 has a 10.6-hour half-life, distinguishing it from lutetium and actinium. The phase one explored schedules from every six weeks to weekly, with no dose-limiting toxicities observed. The phase two evaluates ADVC001 across three prostate cancer populations, hormone-sensitive suboptimal responders, pre-chemotherapy mCRPC, and post-lutetium PSMA, using an induction-plus-maintenance regimen with adaptive dosing at two randomized dose levels.
Dr. Oliver Sartor interviews AdvanCell CMO Dr. Anna Karmann on TheraPb Phase 2 for UroToday
